Markku Jalkanen, chief executive of (), updates Proactive London's Andrew Scott following the release of their 2018 results.
The company's main focus recently has been on Clevegen, its cancer immunotherapy which is currently undergoing a phase I/II study.
Meanwhile a second phase III study is now planned for its Traumakine treatment, subject to approval from regulators and external funding.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE